Payment overview · 2025
General Payments
$992.23
61 reported records · 17 companies
Healthcare provider profile · identity verified
Marek Robert Lupicki, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · OLD BRIDGE, NJ · NPI 1508967746
Verified facts
What the public records show
CMS Open Payments records show Marek Robert Lupicki, M.D. received $992.23 in general payments during 2025 across 61 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 24 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Jardiance, Ozempic, Rybelsus, Synthroid, Trelegy Ellipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 30 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 119 claims for Jardiance by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 464 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 73 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 464 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $272.23 | 27.4% | 15 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $91.30 | 9.2% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $77.42 | 7.8% | 5 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $76.90 | 7.8% | 5 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $64.35 | 6.5% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $61.65 | 6.2% | 4 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $53.65 | 5.4% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $50.21 | 5.1% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $44.93 | 4.5% | 3 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $40.60 | 4.1% | 2 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $36.04 | 3.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $31.68 | 3.2% | 2 | 2025 |
| Kowa Pharmaceuticals America, Inc. | Unresolved — no canonical attribution shown | $31.47 | 3.2% | 2 | 2025 |
| Collegium Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $17.95 | 1.8% | 1 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $14.25 | 1.4% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $13.90 | 1.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $13.70 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $992.23 | 61 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $191.12 | 10 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $119.92 | 6 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $91.30 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $77.42 | 5 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $76.90 | 5 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $64.35 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $62.64 | 4 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $60.35 | 4 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $53.65 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $50.29 | 3 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $50.21 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $44.93 | 3 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $40.60 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $31.68 | 2 | 2025 |
Source payment records
|
|||||
| ZORYVE Normalized: zoryve |
Drug | Kowa Pharmaceuticals America, Inc. | $31.47 | 2 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $31.14 | 2 | 2025 |
Source payment records
|
|||||
| Belbuca Normalized: belbuca |
Drug | Collegium Pharmaceutical, Inc. | $17.95 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $14.82 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.34 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $14.26 | 1 | 2025 |
Source payment records
|
|||||
| Arikayce Normalized: arikayce |
Drug | Insmed, Inc. | $13.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $13.79 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $13.70 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 464 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 64 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 119 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 30 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 73 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
30 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
64 | 15 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
119 | 26 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
464 | 54 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
73 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 14 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
464 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 821 | 181 |
| Alprazolam | Alprazolam | 614 | 109 |
| Amlodipine Besylate | Amlodipine Besylate | 599 | 144 |
| Levothyroxine Sodium | Levothyroxine Sodium | 598 | 126 |
| Eliquis | Apixaban | 464 | 54 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 459 | 127 |
| Pantoprazole Sodium | Pantoprazole Sodium | 454 | 108 |
| Metoprolol Succinate | Metoprolol Succinate | 409 | 107 |
| Gabapentin | Gabapentin | 385 | 73 |
| Furosemide | Furosemide | 335 | 84 |
| Losartan Potassium | Losartan Potassium | 293 | 61 |
| Tramadol Hcl | Tramadol Hcl | 291 | 62 |
| Metformin Hcl | Metformin Hcl | 259 | 65 |
| Metoprolol Tartrate | Metoprolol Tartrate | 236 | 54 |
| Sertraline Hcl | Sertraline Hcl | 234 | 41 |
| Omeprazole | Omeprazole | 224 | 53 |
| Lisinopril | Lisinopril | 215 | 65 |
| Tamsulosin Hcl | Tamsulosin Hcl | 213 | 48 |
| Glimepiride | Glimepiride | 211 | 60 |
| Metformin Hcl Er | Metformin Hcl | 199 | 51 |
| Oxycodone Hcl | Oxycodone Hcl | 199 | 28 |
| Simvastatin | Simvastatin | 190 | 48 |
| Mirtazapine | Mirtazapine | 184 | 40 |
| Divalproex Sodium | Divalproex Sodium | 181 | 18 |
| Quetiapine Fumarate | Quetiapine Fumarate | 179 | 24 |
| Warfarin Sodium | Warfarin Sodium | 175 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 168 | 29 |
| Potassium Chloride | Potassium Chloride | 162 | 41 |
| Montelukast Sodium | Montelukast Sodium | 154 | 43 |
| Trazodone Hcl | Trazodone Hcl | 154 | 23 |
| Famotidine | Famotidine | 144 | 38 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 142 | 32 |
| Prednisone | Prednisone | 136 | 49 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 135 | 38 |
| Clopidogrel | Clopidogrel Bisulfate | 132 | 41 |
| Clonazepam | Clonazepam | 131 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 128 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 127 | 40 |
| Pravastatin Sodium | Pravastatin Sodium | 127 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 123 | 38 |
| Azithromycin | Azithromycin | 122 | 95 |
| Memantine Hcl | Memantine Hcl | 122 | 22 |
| Jardiance | Empagliflozin | 119 | 26 |
| Buspirone Hcl | Buspirone Hcl | 117 | 15 |
| Fluticasone Propionate | Fluticasone Propionate | 110 | 43 |
| Levetiracetam | Levetiracetam | 109 | 19 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 107 | 63 |
| Allopurinol | Allopurinol | 105 | 27 |
| Meloxicam | Meloxicam | 101 | 30 |
| Lactulose | Lactulose | 99 | 18 |
| Ozempic | Semaglutide | 91 | 14 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 87 | 20 |
| Atenolol | Atenolol | 86 | 23 |
| Donepezil Hcl | Donepezil Hcl | 86 | 18 |
| Nebivolol Hcl | Nebivolol Hcl | 86 | 25 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 85 | 26 |
| Zolpidem Tartrate | Zolpidem Tartrate | 85 | 30 |
| Lorazepam | Lorazepam | 83 | 24 |
| Carvedilol | Carvedilol | 82 | 22 |
| Clonidine Hcl | Clonidine Hcl | 82 | 23 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 80 | 17 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 78 | suppressed |
| Temazepam | Temazepam | 78 | 15 |
| Spironolactone | Spironolactone | 73 | 19 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 73 | 13 |
| Ezetimibe | Ezetimibe | 70 | 18 |
| Finasteride | Finasteride | 69 | 11 |
| Cefuroxime | Cefuroxime Axetil | 67 | 54 |
| Farxiga | Dapagliflozin Propanediol | 64 | 15 |
| Ibuprofen | Ibuprofen | 63 | 18 |
| Nifedipine Er | Nifedipine | 62 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 16 |
| Tizanidine Hcl | Tizanidine Hcl | 59 | 19 |
| Benazepril Hcl | Benazepril Hcl | 57 | 16 |
| Celecoxib | Celecoxib | 56 | 21 |
| Diazepam | Diazepam | 56 | 13 |
| Risperidone | Risperidone | 56 | suppressed |
| Primidone | Primidone | 55 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 54 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 53 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 52 | 23 |
| Irbesartan | Irbesartan | 51 | 16 |
| Doxazosin Mesylate | Doxazosin Mesylate | 50 | 18 |
| Fluoxetine Hcl | Fluoxetine Hcl | 50 | 13 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 50 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 50 | 14 |
| Januvia | Sitagliptin Phosphate | 49 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 48 | 12 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 46 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 45 | 12 |
| Amoxicillin | Amoxicillin | 44 | 27 |
| Scopolamine | Scopolamine | 44 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 43 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 43 | 28 |
| Baclofen | Baclofen | 43 | suppressed |
| Glipizide Er | Glipizide | 43 | suppressed |
| Hydrocortisone | Hydrocortisone | 43 | 13 |
| Xarelto | Rivaroxaban | 42 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 40 | 25 |
| Bupropion Xl | Bupropion Hcl | 39 | suppressed |
| Lidocaine | Lidocaine | 39 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 38 | 13 |
| Lamotrigine | Lamotrigine | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 25 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 35 | 23 |
| Nystatin | Nystatin | 35 | 15 |
| Nystop | Nystatin | 35 | 15 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 34 | 14 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 34 | suppressed |
| Aripiprazole | Aripiprazole | 33 | suppressed |
| Oxycontin | Oxycodone Hcl | 33 | suppressed |
| Repaglinide | Repaglinide | 33 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 33 | suppressed |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 32 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 32 | 25 |
| Sucralfate | Sucralfate | 32 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 32 | 11 |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 31 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 31 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 31 | 24 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 31 | 11 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 30 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 29 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Fluconazole | Fluconazole | 29 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 29 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 29 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 28 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Levofloxacin | Levofloxacin | 28 | 22 |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Bumetanide | Bumetanide | 27 | 11 |
| Methylprednisolone | Methylprednisolone | 27 | 14 |
| Ramipril | Ramipril | 27 | suppressed |
| Multaq | Dronedarone Hcl | 26 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 25 | suppressed |
| Buprenorphine | Buprenorphine | 25 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 25 | suppressed |
| Olanzapine | Olanzapine | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Torsemide | Torsemide | 25 | suppressed |
| Vascepa | Icosapent Ethyl | 25 | suppressed |
| Brilinta | Ticagrelor | 24 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 24 | suppressed |
| Azathioprine | Azathioprine | 23 | suppressed |
| Cilostazol | Cilostazol | 23 | suppressed |
| Fenofibric Acid | Fenofibric Acid (Choline) | 23 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 22 | suppressed |
| Enoxaparin Sodium | Enoxaparin Sodium | 22 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Linzess | Linaclotide | 22 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Kapspargo Sprinkle | Metoprolol Succinate | 21 | suppressed |
| Latanoprost | Latanoprost | 21 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 20 | suppressed |
| Testosterone | Testosterone | 20 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 19 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 19 | suppressed |
| Briviact | Brivaracetam | 18 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 18 | suppressed |
| Methimazole | Methimazole | 18 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 18 | suppressed |
| Metronidazole | Metronidazole | 18 | 16 |
| Morphine Sulfate Er | Morphine Sulfate | 18 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Etodolac | Etodolac | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 17 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 15 |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Cephalexin | Cephalexin | 16 | suppressed |
| Lansoprazole | Lansoprazole | 16 | suppressed |
| Nyamyc | Nystatin | 16 | 12 |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 16 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 15 | suppressed |
| Folic Acid | Folic Acid | 15 | suppressed |
| Lacosamide | Lacosamide | 15 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 15 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 15 | suppressed |
| Carisoprodol | Carisoprodol | 14 | suppressed |
| Restasis | Cyclosporine | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Levoxyl | Levothyroxine Sodium | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Oxymorphone Hcl Er | Oxymorphone Hcl | 13 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 13 | suppressed |
| Silver Sulfadiazine | Silver Sulfadiazine | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 12 | suppressed |
| Cefdinir | Cefdinir | 12 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 12 | suppressed |
| Fenofibrate | Fenofibrate | 12 | suppressed |
| Glyxambi | Empagliflozin/Linagliptin | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Mounjaro | Tirzepatide | 12 | suppressed |
| Paliperidone Er | Paliperidone | 12 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 11 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 11 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 11 | suppressed |
| Estradiol | Estradiol | 11 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 11 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $992.23 · 61 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, Arikayce, Belbuca, CAMZYOS, Cologuard Collection Kit, ELIQUIS, FARXIGA, JARDIANCE, Kerendia, Korlym, NURTEC ODT, OTEZLA, Ozempic, QULIPTA, REPATHA, REXULTI, Rybelsus, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, VOQUEZNA, Wegovy, ZAVZPRET, ZORYVE | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error